Business
AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
Dostarlimab royalties to AnaptysBio increase from 4-8% to 8-25% of global net sales, with first US approval in endometrial cancer anticipated in Q4
About this update from Anaptysbio, Inc.
[{"type":"text","content":"Dostarlimab royalties to AnaptysBio increase from 4-8% to 8-25% of global net sales, with first US approval in endometrial cancer anticipated in Q4 2020Additional 1% royalty to AnaptysBio on GSK’s global net sales of Zejula™ (niraparib) starting January 2021GSK to pay one-time cash payment of $60MM to AnaptysBio within 30 daysGSK obtains freedom to develop and commercialize Zejula™ in combination with third party molecules$75MM in dostarlimab FDA BLA and EMA MAA regulatory filing and approval cash milestones anticipated by AnaptysBio in upcoming 18 months SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that AnaptysBio and GlaxoSmithKline (GSK) have amended their immuno-oncology collaboration agreement. The amended agreement provides AnaptysBio with increased royalties on dostarlimab sales under the collaboration, a royalty on GSK’s Zejula™ and a one-time cash payment. GSK receives freedom to conduct combination development and commercialization of Zejula™ with third party molecules.\n “We are pleased to continue our strategic immuno-oncology collaboration with GSK and look forward to the anticipated first FDA approval of dostarlimab,” said Hamza Suria, chief executive officer of AnaptysBio. “The three clinical-stage antibodies under this collaboration were generated by AnaptysBio using our somatic hypermutation technology platform. While our internal focus is the advancement of AnaptysBio’s wholly-owned first-in-class anti-inflammatory antibody pipeline, we are pleased to partner with GSK in advancing novel immuno-oncology therapies for patients suffering with cancer.” Originally signed with Tesaro in March 2014, the GSK collaboration is focused on advancing checkpoint receptor antagonist antibodies against PD-1, TIM-3 and LAG-3 in oncology. Dostarlimab is an anti-PD-1 antagonist antibody currently under development by GSK for multiple oncological disorders, including endometrial cancer, non-small cell lung cancer, ovarian cancer, colorectal cancer and mismatch repair deficient solid tumors. Cobolimab, an anti-TIM-3 antagonist antibody, and GSK4069889A, an anti-LAG-3 antagonist antibody, ...